Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves’ Hyperthyroidism: A Randomized Controlled Study
Table 1
Baseline characteristics of hyperthyroid patients treated with 15 mg/day OD-MMI and 15 mg/day DD-MMI.
15 mg/day OD-MMI
15 mg/day DD-MMI
value
Total number of patients (cases)
21
23
Sex: females/males (cases)
13/8
20/3
0.083
Age (years)
36.67 ± 12.53
41.74 ± 13.52
0.205
Duration of symptoms (months)
4.11 ± 3.84
3.43 ± 2.50
0.914
Body weight (kg)
58.31 ± 9.55
55.28 ± 10.71
0.329
Weight loss (kg/month)
2.41 ± 4.35
1.70 ± 1.80
0.492
Goiter size (g)
25.95 ± 18.14
23.04 ± 12.13
0.532
Serum FT3 (pmol/L)
29.24 ± 14.12
23.96 ± 13.74
0.216
Serum FT4 (pmol/L)
68.47 ± 27.80
56.76 ± 23.94
0.141
Serum TSH (mIU/L)
0.0074 ± 0.0026
0.0083 ± 0.0039
0.401
Serum ALT (IU/dL)
31.24 ± 14.61
33.56 ± 23.97
0.703
Serum AST (IU/dL)
27.14 ± 7.38
29.30 ± 15.02
0.554
Data are demonstrated as mean ± standard deviation. 15 mg/day OD-MMI, 15 mg/day of methimazole administered once daily; 15 mg/day DD-MMI, 15 mg/day of methimazole administered dividedly in 5 mg three times a day.
